The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Advances in CLL at ASH 2020: combination therapies
John Allan, MD, Weill Cornell Medicine, New York, NY, highlights the upcoming advances in the field of chronic lymphocytic leukemia (CLL) at ASH 2020. The field is now moving away from monotherapies and sequencing type approaches to optimizing how best to combine existing therapies such as Burton’s tyrosine kinase (BTK) inhibitors, venetoxclax, and anti-CD20 antibodies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
John Allan, MD, has done consultancy work, participated in advisory boards and/or received honoraria from Pharmacyclics, Janssen, Abbvie, BeiGene, Genentech and AstraZeneca; and has received research Funding from Genentech, Janssen and TG Therapeutics.
